The dismissal of Borgers by Sunshine Biopharma following a settlement with the SEC suggests potential concerns about the integrity of financial reporting. This action could lead to short-term negative sentiment among investors due to uncertainties regarding the company's financial oversight and the need to find a new independent accountant.